Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Teresa Alonso‐Gordoa"'
Autor:
Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, Paula Jimenez-Fonseca, Alex Teule, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso-Gordoa, Ana Custodio, Beatriz Anton-Pascual, Jorge Hernando, Eduardo Polo, Oscar Alfredo Castillo-Trujillo, Arantza Lamas-Paz, Ana Teijo, Yolanda Rodriguez-Gil, Beatriz Soldevilla, Rocio Garcia-Carbonero
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is a s
Externí odkaz:
https://doaj.org/article/6981a3198f934da4bebd41d0dfe4b108
Autor:
Jarushka Naidoo, Maria L Ascierto, Matthew D Hellmann, Ding Wang, Susana Banerjee, Mayukh Das, Panagiotis Kourtesis, Jennifer R Diamond, Teresa Alonso-Gordoa, Sandip P Patel, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Benedito A Carneiro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background The combination of monalizumab (anti-NKG2A/CD94) and durvalumab (anti-programmed death ligand-1) may promote antitumor immunity by targeting innate and adaptive immunity. This phase 1/2 study of monalizumab and durvalumab evaluated safety,
Externí odkaz:
https://doaj.org/article/53d0d5cbaca340b3995a64a938291778
Autor:
Teresa Alonso‐Gordoa
Publikováno v:
Cancer Medicine, Vol 11, Iss S1, Pp 33-39 (2022)
Abstract The diagnosis of central nervous system metastases in patients with radioiodine refractory differentiated thyroid cancer is a late and rare event that occurs in less than 1% of patients. Definitive conclusions on the overall clinical managem
Externí odkaz:
https://doaj.org/article/4eecda334ce94586baaf962dbed0d308
Autor:
Joan Brunet, Josep Tabernero, Salvatore Grisanti, Matteo Lambertini, George Pentheroudakis, Bruno Vincenzi, Dirk Arnold, Juan Aguilar-Company, Paolo Pedrazzoli, Solange Peters, Luis Castelo-Branco, Emanuela Romano, Olivier Michielin, Ramon Salazar, Alessio Cortellini, Rossana Berardi, Aleix Prat, Spyridon Gennatas, Giuseppe Tonini, Urania Dafni, Kevin J Harrington, Paola Queirolo, David J Pinato, Francesca Mazzoni, David Viñal, Gino M Dettorre, Uma Mukherjee, Mark Bower, Alexia Bertuzzi, Ailsa Sita-Lumsden, Federica Biello, Andrea Patriarca, Alessandra Gennari, Maura Rossi, Zoi Tsourti, Vasileios Angelis, Jacobo Rogado, Teresa Alonso-Gordoa, Georgia Dimopoulou, Sylvain Pradervand, Marco Tucci, Fanny Pommeret, Marco Krengli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer.Methods In a joint analysis of ICI recip
Externí odkaz:
https://doaj.org/article/b011e59004e14e2dab36152831044c2b
Autor:
Aurora Gómez-Vecino, Roberto Corchado-Cobos, Adrián Blanco-Gómez, Natalia García-Sancha, Sonia Castillo-Lluva, Ana Martín-García, Marina Mendiburu-Eliçabe, Carlos Prieto, Sara Ruiz-Pinto, Guillermo Pita, Alejandro Velasco-Ruiz, Carmen Patino-Alonso, Purificación Galindo-Villardón, María Linarejos Vera-Pedrosa, José Jalife, Jian-Hua Mao, Guillermo Macías de Plasencia, Andrés Castellanos-Martín, María del Mar Sáez-Freire, Susana Fraile-Martín, Telmo Rodrigues-Teixeira, Carmen García-Macías, Julie Milena Galvis-Jiménez, Asunción García-Sánchez, María Isidoro-García, Manuel Fuentes, María Begoña García-Cenador, Francisco Javier García-Criado, Juan Luis García-Hernández, María Ángeles Hernández-García, Juan Jesús Cruz-Hernández, César Augusto Rodríguez-Sánchez, Alejandro Martín García-Sancho, Estefanía Pérez-López, Antonio Pérez-Martínez, Federico Gutiérrez-Larraya, Antonio J. Cartón, José Ángel García-Sáenz, Ana Patiño-García, Miguel Martín, Teresa Alonso-Gordoa, Christof Vulsteke, Lieselot Croes, Sigrid Hatse, Thomas Van Brussel, Diether Lambrechts, Hans Wildiers, Hang Chang, Marina Holgado-Madruga, Anna González-Neira, Pedro L. Sánchez, Jesús Pérez Losada
Publikováno v:
Cells, Vol 12, Iss 15, p 1956 (2023)
Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, but we cannot predict who may suffer from this complication. CDA is a complex trait with a polygenic component that is mainly unidentified. We propose that levels of intermediate mol
Externí odkaz:
https://doaj.org/article/30117a66c9fb4e32901af4d0a0a24d13
Publikováno v:
Medicina Clínica Práctica, Vol 2, Iss 3, Pp 47-50 (2019)
Resumen: Introducción: Los tumores indiferenciados de senos paranasales son una rara entidad con una baja incidencia de presentación. A día de hoy no existe un tratamiento estándar aprobado para estos pacientes. Pacientes y métodos: Se presenta
Externí odkaz:
https://doaj.org/article/9feba5a947e14f0cac004b68bde33da5
Publikováno v:
Biomedicines, Vol 9, Iss 3, p 304 (2021)
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options in the advanced stages. Immunotherapy offers hope for altering the orthodox management of cancer, and its role in advanced ACC has been investigated in diffe
Externí odkaz:
https://doaj.org/article/c0191e9eb57441e7a8f3e1c20adc94a9
Autor:
Olga Martínez-Sáez, Javier Molina-Cerrillo, Carmen Moreno García del Real, Rafael Barberá Durban, Juan J. Díez, Teresa Alonso-Gordoa, Enrique Grande Pulido
Publikováno v:
Case Reports in Otolaryngology, Vol 2016 (2016)
Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies from cells derived from the neural crest with neuroendocrine differentiation. Despite the differences in the site of origin, nomenclature, biological behavior, and functional
Externí odkaz:
https://doaj.org/article/a5c7f2a029814124afab6eeb49228e31
Autor:
Guillermo de Velasco, Teresa Alonso-Gordoa, Alejo Rodríguez-Vida, Georgia Anguera, Marc Campayo, Álvaro Pinto, Esther Martínez Ortega, Enrique Gallardo, Natalia Fernández Núñez, Iciar García-Carbonero, Oscar Reig, María José Méndez-Vidal, Ovidio Fernández-Calvo, Natalia Vidal Cassinello, Dolores Torregrosa, Ana López-Martín, Adriana Rosero, Patricia G. Valiente, Carmen Garcías de España, Miguel A. Climent, Montserrat Domenech Santasusana, Ángel Rodríguez Sánchez, Isabel Chirivella González, Ruth Afonso, Xavier García del Muro, Javier Casinello, Eva M. Fernández-Parra, Lourdes García Sánchez, Javier Afonso, Susana Hernando Polo, Úrsula Asensio
Publikováno v:
Clinical Genitourinary Cancer. 21:e166-e174
The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics of these patients could reveal previously unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d56af2d835c82b836e6a6a737be2ff3d
https://doi.org/10.1016/j.clgc.2022.11.021
https://doi.org/10.1016/j.clgc.2022.11.021
Autor:
María P. Fernandez‐Perez, Enrique Perez‐Navarro, Teresa Alonso‐Gordoa, Vicenza Conteduca, Albert Font, Sergio Vázquez‐Estévez, Aránzazu González‐del‐Alba, Daniel Wetterskog, Emmanuel S. Antonarakis, Begona Mellado, Ovidio Fernandez‐Calvo, María J. Méndez‐Vidal, Miguel A. Climent, Ignacio Duran, Enrique Gallardo, Angel Rodriguez Sanchez, Carmen Santander, Maria I. Sáez, Javier Puente, Julian Tudela, Alberto Martínez, Maria J. López‐Andreo, José Padilla, Rebeca Lozano, David Hervas, Jun Luo, Ugo de Giorgi, Daniel Castellano, Gerhardt Attard, Enrique Grande, Enrique Gonzalez‐Billalabeitia
Publikováno v:
The Prostate. 83:376-384
Background There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). Methods We conducted a phase II trial of enzalutamide in first-line chemo-na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73193786f45472a6e4883af37944503c
https://doi.org/10.1002/pros.24469
https://doi.org/10.1002/pros.24469